Michael Mosley's Widow Reveals Moment She Realised 'Something Had Gone Terribly Wrong' To British TV Presenter Who Died On Greek Island
Michael Mosley's widow has revealed the moment she realised something terribly wrong had happened to her husband, who died on the Greek island of Symi a year ago.
The popular UK doctor and TV presenter had just arrived on holiday on June 5 2024 with his wife and friends, when he went missing following his decision to walk alone back to their villa from a nearby beach.
More from Deadline
Mystery Solved Of Why TV Doctor Michael Mosley Left Phone At Home Before He Died
'Peter Five Eight' Joins Jinga's AFM Slate; 'Knockout Blonde' Domestic Deal; OUTtv Co-Commissions Latest 'Glow Up'; Late Michael Mosley Honored - Global Briefs
Michael Mosley: Paramount's Channel 5 Faces Dilemma Over Airing Presenter's 'Wonders Of The Human Body' Series
Dr Clare Bailey told the Daily Mail newspaper this weekend that it was only when she got back to the villa later in the day she realised her husband was missing. Once the alarm was raised, she remained hopeful he would be found on a neighbouring path, particularly after locals turned out in their dozens to help authorities with the search.
However, with the arrival of night-time came her despair at her husband being found safe. Bailey told the Daily Mail:
'Then it got dark. It became devastatingly obvious something had gone terribly wrong.'
Poignantly, Mosley didn't have his mobile phone with him because, Bailey explained, 'he didn't want to risk it getting wet on the boat.'
Four days after he went missing, Mosley's body was found only 100 yards away from a waterside restaurant. It was apparent he had lost his bearings, then stumbled and fallen in the heat.
Huge tributes were paid to the popular writer and presenter, who made TV programmes and podcasts exploring nutrition and wrote bestselling books about the benefits of fasting and ways it was possible to reverse Type Two Diabetes.
Dr Clare Bailey had been married to Mosley since 1997, and often appeared alongside him on his popular TV programmes exploring nutrition and wellbeing. Additionally, she frequently co-authored on his bestselling books.
She said this weekend, almost one year after losing her husband:
'Michael loved exploring. That was the joy of him,' she says. 'His death was in keeping with his life.
'He was a maverick, a bit of a risk-taker. He pushed boundaries. I loved him for that; it made him so special. He was unorthodox and just so brilliant.
'Others went to look at the place where he died. I just didn't want to know too much about it. All I really wanted to know was that he was not suffering or in pain.
'He was in a very beautiful place and he so very nearly made it. Actually, I take comfort from that.'
Best of Deadline
Sean 'Diddy' Combs Sex-Trafficking Trial Updates: Cassie Ventura's Testimony, $10M Hotel Settlement, Drugs, Violence, & The Feds
'Poker Face' Season 2 Guest Stars: From Katie Holmes To Simon Hellberg
2025-26 Awards Season Calendar: Dates For Tonys, Emmys, Oscars & More
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS)1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients," said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. "These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients." This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition studyPSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan)Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT)Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media RelationsE-mail: Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Dior picks Jonathan Anderson as creative director, FT reports
(Reuters) - Northern Irish designer Jonathan Anderson has been named creative director of women's, men's and haute couture collections of Dior, replacing Maria Grazia Chiuri who held the role for almost a decade, the Financial Times reported on Monday. Reuters could not immediately confirm the report. Chiuri left her job as creative director of Dior women's collections, the luxury fashion brand owned by LVMH said on May, with Dior menswear designer Anderson widely tipped to take a bigger role.
Yahoo
an hour ago
- Yahoo
WISeKey's WISe.ART 3.0, One of the World's First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN's MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30
WISeKey's 3.0, One of the World's First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN's MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30 pm Geneva, Switzerland – June 2, 2025 — WISeKey International Holding Ltd ('WISeKey') (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, is proud to announce that it will present Faben's holograms for the first time at Lisbon NFC. There will be a live performance by Faben as well as a live discussion with Art Director on stage. Since its launch in 2021, the NFT platform developed by WISeKey, has led numerous high-impact and pioneering NFT projects. Combining trusted digital identity, robust cybersecurity, and environmental consciousness, has redefined how digital art and luxury collectibles are created, verified, and traded. has distinguished itself by ensuring secure digital identity and compliance with international standards, making it one of the few platforms trusted for institutional and philanthropic NFT use cases. Faben's holograms are part of an important project including NFTs, NFCs, physical pieces, and an AI community building app to be developed to bring global beauty and peace. MLove will be developed into a game, an interactive companion, and health and educational guidance in an artistic way to spread the message of love to its community. Revolutionizing the Future of Art- A world premiere that a hologram and a token are linked to a RWA (Real World Asset) About The platform redefines the digital art experience by providing creators and collectors with a secure, traceable, and intelligent environment for trading and authenticating digital assets. It is democratizing digital expression by empowering billions of people worldwide to create, share, and monetize their artistic visions through a secure and trusted platform. Whether it's a digitally generated painting, a collectible tied to a physical sculpture, or a new form of cultural expression, enables creators from all backgrounds to participate in the global digital art economy, safely and transparently. For more information, visit About FABEN: Faben the heArtist, (sculpture, painting, murals, installations worldwide),Creator of MLOVE & NFTH concept - Faben joined the new enhanced platform in time for NFC Lisbon with a collection of holograms announcing the project. The holograms will be identifiable with WISeKEY chips and linked to their respective NFTs on one of the blockchains. The complete NFT collection will be dropped later in July during ARTMONACO week. Faben is an internationally renowned artist for his Mr Love sculpture spreading goodwill to all generations with inventive art using technology to reach new frontiers in communication. About NFC Summit: Is the major annual event where the creative economy meets WEB 3 – Art Fashion, Gaming and Music, live performance stage, blending virtual and reality in unprecedented ways. The world's major web3 players, investors and media from around the world gather to present and discuss current trends. Live performances, conference on multiple stages, awards and exhibitions will be open to the public for 3 crazy days in an historical venue in the heart of Lisbon. About WISeKey WISeKey International Holding Ltd ('WISeKey', SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) Corp which focuses on trusted blockchain NFTs and operates the marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN subsidiary contributes to WISeKey's mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company's semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey's strategic direction and its subsidiary companies, please visit DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act ('FinSA'), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@ PTY LTDCompany Contact: S. CrutchfieldArt DirectorTel: +41 22 594 3000scrutchfield@ WISeKey Investor Relations (US) The Equity Group CatiTel: +1 212 836-9611 lcati@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
